To be effective, cancer detection needs to be simple, readily available, and affordable. We develop innovative products that quickly and reliably identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer. To meet this demand, the Mainz Biomed Group, together with its subsidiaries, develops targeted solutions for patients around the globe.
The following companies are part of the Mainz Biomed Group.
Mainz Biomed N.V.
The parent company, headquartered in Mainz, Germany, successfully completed an IPO on the US stock exchange “NASDAQ” in 2021 and forms the strategic backbone of the Group.
Mainz Biomed N.V. Robert-Koch-Straße 50, 55129 Mainz, Germany
Mainz Biomed USA, Inc.
Our U.S. subsidiary focuses on the preparation and implementation of U.S. clinical trials and pursues the intermediate goal of FDA approval for our products.
Mainz Biomed USA, Suite 300, 2001 Addison St, Berkeley, CA 94704, United States
Mainz Biomed Germany GmbH
The European arm of the group is located in the biotechnology capital Mainz, Germany. Both product development and the commercial expansion of our product portfolio are based here.
Mainz Biomed Germany GmbH, Robert-Koch-Straße 50, 55129 Mainz, Germany
European Oncology Lab GmbH
To offer patients easy, fast, and affordable access to cutting-edge diagnostic products, the European Oncology Lab, based in St. Ingbert, Germany, was founded. Routine diagnostics for German and European patients take place here.
European Oncology Lab GmbH, Klaus-Tussing-Str. 2 / Gesundheitspark 2, 66386 St. Ingbert, Germany
